Cyclerion Therapeutics (NASDAQ:CYCN) Coverage Initiated at Cantor Fitzgerald

Analysts at Cantor Fitzgerald began coverage on shares of Cyclerion Therapeutics (NASDAQ:CYCN) in a research note issued to investors on Friday, Analyst Price Targets reports. The firm set an “overweight” rating and a $7.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 107.10% from the stock’s previous close.

CYCN stock opened at $3.38 on Friday. The company has a 50-day simple moving average of $3.19 and a 200 day simple moving average of $3.26. Cyclerion Therapeutics has a fifty-two week low of $2.08 and a fifty-two week high of $7.55.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings data on Thursday, July 29th. The company reported ($0.45) earnings per share for the quarter. The company had revenue of $3.00 million during the quarter. Cyclerion Therapeutics had a negative return on equity of 108.85% and a negative net margin of 1,880.97%.

Institutional investors have recently modified their holdings of the business. Walleye Trading LLC bought a new stake in Cyclerion Therapeutics in the first quarter worth about $28,000. XTX Topco Ltd bought a new stake in Cyclerion Therapeutics in the first quarter worth about $37,000. Walleye Capital LLC acquired a new stake in Cyclerion Therapeutics during the 1st quarter worth about $42,000. Barclays PLC raised its holdings in Cyclerion Therapeutics by 159.0% during the 1st quarter. Barclays PLC now owns 18,516 shares of the company’s stock worth $52,000 after buying an additional 11,367 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Cyclerion Therapeutics during the 2nd quarter worth about $67,000. Hedge funds and other institutional investors own 56.91% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP).

Read More: What are the advantages to having securities held in street name?

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.